Adverum Biotechnologies, Inc. (ADVM)
NASDAQ: ADVM · Real-Time Price · USD
7.54
+0.13 (1.75%)
Nov 4, 2024, 4:00 PM EST - Market closed
Adverum Biotechnologies Revenue
In the year 2023, Adverum Biotechnologies had annual revenue of $3.60M.
Revenue (ttm)
$3.60M
Revenue Growth
n/a
P/S Ratio
128.83
Revenue / Employee
$8,264
Employees
121
Market Cap
156.84M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionADVM News
- 10 hours ago - Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones - GlobeNewsWire
- 19 days ago - Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program - GlobeNewsWire
- 2 months ago - Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences - GlobeNewsWire
- 3 months ago - Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference - GlobeNewsWire
- 3 months ago - Adverum Biotechnologies, Inc's (ADVM) 26-Week Interim Analysis of the LUNA Phase 2 Trial Update Transcript - Seeking Alpha
- 3 months ago - Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting - GlobeNewsWire
- 6 months ago - Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights - GlobeNewsWire